logo
Delaney requests $41 million for 6th District

Delaney requests $41 million for 6th District

Yahoo2 days ago

CUMBERLAND — U.S. Rep. April McClain Delaney announced last week that she has requested over $41 million of federal funds for local investments in Maryland's 6th Congressional district for the next fiscal year.
Out of the 15 Community Project Funding requests made, seven would support a wide range of efforts in Allegany and Garrett counties, allocating over $7 million in Allegany County and over $8 million in Garrett County, according to a press release.
'I know how important it is to work hand-in-hand with local leaders to achieve real results,' McClain Delaney said in the announc ement. 'Since taking office in January, I've engaged with state and community officials to identify projects that will make the biggest difference and support those who need it most.'
Many of the projects would restore water infrastructure, like replacing the water filtration system in Cumberland, which will cost $2 million.
'The existing plant is reaching the end of its useful life and is incapable of addressing emerging contaminants,' Cumberland Mayor Ray Morriss said. 'This grant will allow the city to begin design work on a new Water Filtration Building that will utilize state-of-the-art membrane filtration, which is capable of removing disinfection byproducts as well as emerging contaminants.'
About $1.3 million of improvements to Lonaconing's water lines were included in the requests as well.
'This investment in our Western Maryland community will aid in improving the quality of life by ensuring reliable access to clean and safe drinking water for our residents and providing peace of mind by reducing concerns about water quality or potential service disruptions,' Lonaconing Mayor Jack Coburn said.
About $6.2 million would go toward other infrastructure projects in the two counties, including improvements on Oakland's water system, a sidewalk and crosswalk safety project in Grantsville and replacing a Potomac Fire Company No. 2 engine.
'Upgrading our aging water and sewer infrastructure will not only improve service reliability and water quality but also help prevent future system failures and environmental hazards,' Oakland Mayor Andrew Sauder said. 'This project is a critical step toward ensuring a sustainable and secure future for Oakland residents.'
Among the requests, a $3 million expansion of the radiology and oncology department in Garrett Regional Medical Center in Oakland focuses on the expansion of medical resources.
'This funding, which supports the design and engineering phase of adding radiation oncology to our Cancer Center, means we will largely eliminate the need for cancer patients to travel to receive the care they need,' Mark Boucot, the chief executive of the center, said.
Another project would contribute to educational resources, spending about $2.8 million on revitalizing the Frostburg State University Planetarium.
'The revitalized planetarium will not only enhance educational opportunities for a diversity of learners of all ages, but will also contribute to cultural and economic growth,' said Associate Professor of Physics Jason Speights.
The remaining $26 million would go toward projects in the rest of the congressional district throughout Washington and Frederick counties.
'These community-focused investments will help foster growth and strengthen Maryland's 6th Congressional District,' McClain Delaney said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

Yahoo

time22 minutes ago

  • Yahoo

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau. Per the terms of the agreement, Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achievement of development, regulatory and sales milestones. Any royalties on global net sales in the future (outside the designated territories) would be in the low double digits. HS-20094 has been evaluated in over 1,000 patients and administered as a weekly subcutaneous injection. The candidate has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist. The candidate is currently being evaluated in a phase III study in obesity in China, and a phase IIb study in diabetes is ongoing. The in-licensing agreement for an obesity candidate will expand REGN's obesity pipeline, which includes trevogrumab. Regeneron recently announced positive interim results from the ongoing phase II COURAGE study investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity. COURAGE was designed to investigate the quality of weight loss in patients with obesity. Results showed that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass. Garetosmab is being evaluated for the treatment of fibrodysplasia ossificans progressive. The successful development of any obesity treatment will be a great boost for the company. We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi SNY reported results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD). While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same. REGN and SNY are currently reviewing the data and plan to discuss the next steps with regulatory authorities. Year to date, REGN's shares have lost 31.7% compared with the industry's 3.2% decline. Image Source: Zacks Investment Research Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line. Eylea sales have been under pressure for some time now due to competition from Roche's Vabysmo. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line. Apart from Eylea, profits from the sales of asthma drug Dupixent are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for Dupixent. While the obesity market is lucrative, REGN is a pretty late entrant here. The market is dominated by bigwigs like Novo Nordisk NVO and Eli Lilly LLY. The stupendous success of Novo Nordisk's obesity drug, Wegovy (semaglutide) and Eli Lilly's Zepbound has prompted many companies to join the bandwagon. Buoyed by this success, both Lilly and NVO have taken significant strides in developing their obesity portfolios further. Given the significant market potential of obesity, other players are also striving to grab a chunk of this pie. Regeneron currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Global Virus Network Issues Scientific Guidance on New COVID-19 Variant NB.1.8.1 and Vaccine Protection
Global Virus Network Issues Scientific Guidance on New COVID-19 Variant NB.1.8.1 and Vaccine Protection

Yahoo

time3 hours ago

  • Yahoo

Global Virus Network Issues Scientific Guidance on New COVID-19 Variant NB.1.8.1 and Vaccine Protection

Scientific collaboration, accurate public communication, and continued investment in prevention tools are critical in navigating the evolving COVID-19 landscape TAMPA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family. This variant was first identified in January 2025 and has rapidly spread across Asia and into other regions, including parts of the United States. The World Health Organization (WHO) has designated NB.1.8.1 as a Variant Under Monitoring due to its increasing prevalence and potential public health implications. Based on current evidence, GVN advises vigilance, not alarm, and reinforces the critical role of vaccination in preventing severe disease and death. Similar to previous Omicron subvariants, NB.1.8.1 contains spike protein mutations associated with increased transmissibility. However, no evidence suggests that NB.1.8.1 causes more severe illness or significantly evades vaccine-induced or natural immunity. Early laboratory and clinical data indicate that updated COVID-19 vaccines, including bivalent and XBB-based boosters, protect against severe outcomes such as hospitalization and death. There is no evidence at this time that NB.1.8.1 causes more severe illness than previous variants. Breakthrough infections may occur, particularly among individuals with waning immunity or those who are unvaccinated. Nevertheless, vaccines remain highly effective in reducing serious illness and death. Antiviral treatments such as nirmatrelvir/ritonavir (Paxlovid) and remdesivir demonstrate efficacy against a range of Omicron subvariants, including BQ.1, BQ.1.1, and XBB.1.5. NB.1.8.1 has been linked to significant increases in COVID-19 cases across several countries. According to the WHO, as of May 18, 2025, the NB.1.8.1 variant has been identified in 22 countries, accounting for 10.7% of global SARS-CoV-2 sequences submitted to the Global Initiative on Sharing All Influenza Data (GISAID) during epidemiological week 17 (April 21–27, 2025). This marks a significant increase from 2.5% four weeks prior. As of June 4, 2025, India reported 4,302 active COVID-19 infections, with nearly 300 new cases recorded within the previous 24 hours. States such as Delhi, Uttar Pradesh, West Bengal, Gujarat, and especially Kerala have experienced a steady rise in cases. During the week of April 27 to May 3, 2025, nearly 6,000 individuals in Taiwan sought medical assistance at hospitals due to COVID-19-related symptoms. This marked a 78% increase from the previous week and represented the fourth consecutive week of rising case numbers. As of early June 2025, in the U.S., more than a dozen cases of the NB.1.8.1 subvariant have been identified in Washington State. The variant was first detected in the U.S. between late March and early April through routine screenings of international travelers at airports in California, Washington State, Virginia, and New York. Subsequent cases have been reported in Ohio, Rhode Island, and Hawaii. In the U.S., there have been about 300 deaths per week from COVID-19 in 2025 through May. Periodic summer surges are anticipated, consistent with seasonal patterns observed in previous years. GVN Supports the Following COVID-19 Vaccine Recommendations: Adults aged 65 and older, and individuals with underlying conditions, should receive an updated COVID-19 booster tailored to circulating variants. All individuals 6 months and older, including children and adolescents, are encouraged to stay current with vaccinations, especially ahead of the fall and winter respiratory seasons. Children 6 months to 17 years of age should receive an age-appropriate, updated COVID-19 vaccine dose if they have not already done so within the past year, as protection from earlier vaccines may wane over time. Pediatric vaccination helps prevent severe outcomes, including hospitalization and multisystem inflammatory syndrome in children (MIS-C). Pregnant individuals are strongly encouraged to stay current on COVID-19 vaccination. Vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants by 61% and protects newborns for up to six months after birth—an especially important window given the high rate of emergency department visits for COVID-19 among infants. Studies have consistently shown that infection during pregnancy increases the risk of preterm birth, miscarriage, fetal death, and long-term neurodevelopmental issues. No safety concerns have been identified regarding vaccination in pregnancy or neonatal outcomes. Those not receiving a COVID-19 booster in the past year should consult a healthcare provider about updated vaccine timing and eligibility. Co-administration of COVID-19 and influenza vaccines is recommended when appropriate. Side effects from both COVID-19 and influenza vaccines are rare, and the cost-benefit of vaccination is heavily in favor of vaccination. The principal benefits of vaccination are preventing severe disease, rather than preventing infection itself. The rapid global spread of NB.1.8.1 underscores the ongoing need for proactive surveillance, timely data sharing, and pandemic preparedness. The appearance of new variants is expected and does not signal a public health emergency. Instead, it is a call to action for continued scientific vigilance and proactive health measures. GVN reiterates that this is an opportunity to prepare, not a reason to panic. Scientific collaboration, accurate public communication, and continued investment in prevention tools will remain critical in navigating the evolving COVID-19 landscape. Media Contact: Nora Samaranayakensamaranayake@ About the Global Virus Network The Global Virus Network (GVN) is a worldwide coalition comprising 80+ Virology Centers of Excellence and Affiliates across 40+ countries, whose mission is to facilitate pandemic preparedness against viral pathogens and diseases that threaten public health globally. GVN advances knowledge of viruses through (i) data-driven research and solutions, (ii) fostering the next generation of virology leaders, and (iii) enhancing global resources for readiness and response to emerging viral threats. GVN provides the essential expertise required to discover and diagnose viruses that threaten public health, understand how such viruses spread illnesses, and facilitate the development of diagnostics, therapies, and treatments to combat them. GVN coordinates and collaborates with local, national, and international scientific institutions and government agencies to provide real-time virus informatics, surveillance, and response resources and strategies. GVN's pandemic preparedness mission is achieved by focusing on Education & Training, Qualitative & Quantitative Research, and Global Health Strategies & Solutions. The GVN is a non-profit 501(c)(3) organization. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

‘Game-Changing' Anti-Ship Weapon Tested by US Stealth Bomber
‘Game-Changing' Anti-Ship Weapon Tested by US Stealth Bomber

Miami Herald

time4 hours ago

  • Miami Herald

‘Game-Changing' Anti-Ship Weapon Tested by US Stealth Bomber

An American stealth bomber recently tested a "game-changing" weapon designed to sink warships amid China's rapid naval buildup to challenge the United States in the Pacific. The new weapon-known as Quicksink-is capable of "rapidly and efficiently" sinking maritime targets, the U.S. Air Force Research Laboratory said in a news release on Wednesday. Newsweek has contacted the Chinese Defense Ministry for comment by email. China has the largest navy in the world by hull count, according to the Pentagon, with more than 370 ships and submarines-including two aircraft carriers in active service-enabling Beijing to expand its military reach and presence within and beyond the western Pacific. Facing China's growing naval threat, the U.S. has been arming its allies and partners in the Pacific-Australia, Japan and Taiwan-with various anti-ship weapons and deploying the Maritime Strike Tomahawk, the ship-sinking variant of the Tomahawk cruise missile. The test-which took place at a Gulf test range near Eglin Air Force Base in northwestern Florida-involved a B-2 stealth bomber and the 500-pound variant of the Quicksink maritime weapon. Official photos indicate the test was conducted in late April. Quicksink is a U.S. Air Force weapons program aimed at creating "air-delivered, low-cost, surface vessel defeat capability" to enhance Washington's power projection and maintain freedom of navigation in critical waterways, the U.S. Air Force Research Laboratory said. The weapon itself is a modified Joint Direct Attack Munition-a family of precision-guided bombs-enhanced with anti-ship capabilities. The 2,000-pound Quicksink variant was successfully tested during an exercise in the Pacific last year, according to the news release. The new, smaller Quicksink variant is modified from the GBU-38 Joint Direct Attack Munition and is set to expand the B-2 bomber's targeting capabilities. The bomber is designed to penetrate the "most sophisticated defenses" and can carry up to 40,000 pounds of weapons. This capability provides a rapid response to maritime threats, the U.S. Air Force Research Laboratory said, significantly bolstering the Air Force's counter-maritime deterrence and operations. However, it remains unclear whether the weapon has been officially fielded. Tom Shugart, a former U.S. Navy submariner and an adjunct senior fellow at the Center for a New American Security, wrote on X, formerly Twitter, that he would be "pretty surprised" if the stealth bomber flew within range of Chinese warships to drop the bomb. "Are we 1,000 percent sure that their air defense systems aren't going to get a sniff?" he asked. The B-2 bomber is one of the U.S. Air Force's most valuable assets, with only 19 aircraft in service. General David Allvin, the U.S. Air Force's chief of staff, wrote on X on Wednesday: "We unleashed a new QUICKSINK weapon, which significantly enhances our ability to strike stationary or moving surface vessels. This is a true game-changer for the [Department of Defense] and is exactly what [President Donald Trump] means by PEACE THROUGH STRENGTH!" The U.S. Air Force Research Laboratory said on its website: "QUICKSINK is an answer to the need to quickly neutralize menacing maritime threats over vast areas around the world. … QUICKSINK is unique because it can provide new capabilities to existing and future DoD weapons systems, giving combatant commanders and our national leaders new ways to defend against maritime threats." It remains to be seen whether the U.S. Air Force and other service branches will develop entirely new weapons or modify existing armaments to neutralize enemy warships. Related Articles Iran to Counter US Nuclear Offer as Trump Sends New WarningHooters Closing Locations Across US: Full List of Restaurants Shutting DownJeffrey Epstein Video Release: What Footage Shows of His DeathImages Show U.S. Patriot Missiles Deployed for Muslim Hajj Pilgrimage 2025 NEWSWEEK DIGITAL LLC.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store